| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $0 | 0 | 0 |
Sells | $752,193 | 17 | 100 |
| See Tai Sandi | Chief Development Officer | 0 | $0 | 1 | $3,578 | $-3,578 |
| Robertson Jenny | Chief Legal Officer | 0 | $0 | 1 | $5,089 | $-5,089 |
| Adler Eric | Chief Medical Officer | 0 | $0 | 1 | $5,701 | $-5,701 |
| Tamayo Louis Edward | Chief Financial Officer | 0 | $0 | 2 | $41,041 | $-41,041 |
| Otero Jose Manuel | Chief Operating Officer | 0 | $0 | 5 | $59,952 | $-59,952 |
| Bhalla Narinder Pal | Chief Medical Officer | 0 | $0 | 1 | $98,593 | $-98,593 |
| Townsend Richard Nolan | Chief Executive Officer | 0 | $0 | 6 | $538,240 | $-538,240 |
Lexeo Therapeutics, Inc. is a genetic medicine firm currently in the clinical development phase, dedicated to addressing both inherited and acquired medical conditions. Its robust pipeline features several gene therapy candidates. These include LX2006, an AAVrh10-based therapy aimed at treating cardiomyopathy linked to Friedreich's ataxia (FA); LX2020, another AAVrh10-based candidate targeting arrhythmogenic cardiomyopathy; LX2021, designed for DSP cardiomyopathy; and LX2022, which focuses on hypertrophic cardiomyopathy (HCM) stemming from …
Over the last 12 months, insiders at Lexeo Therapeutics, Inc. Common Stock have bought $0 and sold $752,193 worth of Lexeo Therapeutics, Inc. Common Stock stock.
On average, over the past 5 years, insiders at Lexeo Therapeutics, Inc. Common Stock have bought $5.05M and sold $403,730 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 15,000 shares for transaction amount of $104,852 was made by CHOLMONDELEY PAULA H (director) on 2024‑11‑25.
| 2026-08-18 | Sale | Townsend Richard Nolan | Chief Executive Officer | 3,345 0.0043% | $4.95 | $16,562 | -29.61% | |
| 2026-08-18 | Sale | Otero Jose Manuel | Chief Operating Officer | 1,304 0.0017% | $4.96 | $6,464 | -29.61% | |
| 2026-08-18 | Sale | Tamayo Louis Edward | Chief Financial Officer | 4,117 0.0052% | $4.91 | $20,203 | -29.61% | |
| 2026-07-01 | Sale | Townsend Richard Nolan | Chief Executive Officer | 25,947 0.0318% | $4.48 | $116,243 | -1.35% | |
| 2026-07-01 | Sale | Otero Jose Manuel | Chief Operating Officer | 4,666 0.0057% | $4.48 | $20,904 | -1.35% | |
| 2026-07-01 | Sale | Tamayo Louis Edward | Chief Financial Officer | 4,641 0.0057% | $4.49 | $20,838 | -1.35% | |
| 2026-07-01 | Sale | Bhalla Narinder Pal | Chief Medical Officer | 22,306 0.027% | $4.42 | $98,593 | -1.35% | |
| 2026-05-18 | Sale | Townsend Richard Nolan | Chief Executive Officer | 3,342 0.0046% | $5.06 | $16,927 | -3.40% | |
| 2026-05-18 | Sale | Otero Jose Manuel | Chief Operating Officer | 1,302 0.0018% | $5.07 | $6,606 | -3.40% | |
| 2026-04-06 | Sale | Townsend Richard Nolan | Chief Executive Officer | 55,000 0.0744% | $5.69 | $313,137 | -18.37% | |
| 2026-02-18 | Sale | Townsend Richard Nolan | Chief Executive Officer | 10,173 0.0141% | $6.38 | $64,924 | -23.05% | |
| 2026-02-18 | Sale | Otero Jose Manuel | Chief Operating Officer | 3,016 0.0042% | $6.40 | $19,294 | -23.05% | |
| 2025-11-18 | Sale | Townsend Richard Nolan | Chief Executive Officer | 1,127 0.0034% | $9.27 | $10,447 | -41.01% | |
| 2025-11-18 | Sale | Adler Eric | Chief Medical Officer | 615 0.0019% | $9.27 | $5,701 | -41.01% | |
| 2025-11-18 | Sale | Robertson Jenny | Chief Legal Officer | 549 0.0017% | $9.27 | $5,089 | -41.01% | |
| 2025-11-18 | Sale | See Tai Sandi | Chief Development Officer | 386 0.0012% | $9.27 | $3,578 | -41.01% | |
| 2025-11-18 | Sale | Otero Jose Manuel | Chief Operating Officer | 721 0.0022% | $9.27 | $6,684 | -41.01% | |
| 2025-10-17 | Sale | Townsend Richard Nolan | Chief Executive Officer | 13,133 0.0369% | $8.94 | $117,436 | -39.77% | |
| 2025-10-17 | Sale | Adler Eric | Chief Medical Officer | 3,382 0.0095% | $8.94 | $30,242 | -39.77% | |
| 2025-10-17 | Sale | Robertson Jenny | Chief Legal Officer | 3,526 0.0099% | $8.94 | $31,530 | -39.77% |
| Longitude Capital Partners IV, LLC | 10 percent owner | 2567100 3.1272% | $7.98M | 1 | 0 | +25.53% |
| Omega Fund VI, L.P. | 10 percent owner | 2157623 2.6284% | $6.71M | 1 | 0 | +25.53% |
| CHOLMONDELEY PAULA H | director | 30627 0.0373% | $95,249.97 | 1 | 0 | <0.0001% |
$6,146,922 | 96 | -4.70% | $233.68M | |
$60,836,085 | 69 | 0.45% | $255.44M | |
$19,239,249 | 50 | -2.24% | $238.33M | |
$109,019,806 | 28 | 7.37% | $263.86M | |
$3,668,031 | 23 | 2.05% | $243.03M |
| Increased Positions | 106 | +126.19% | 34M | +69.06% |
| Decreased Positions | 36 | -42.86% | 7M | -14.11% |
| New Positions | 46 | New | 21M | New |
| Sold Out Positions | 10 | Sold Out | 1M | Sold Out |
| Total Postitions | 154 | +83.33% | 76M | +54.95% |
| Janus Henderson Group Plc | $58,674.00 | 8.36% | 6.11M | +2M | +65.71% | 2025-09-30 |
| Frazier Life Sciences Management, L.P. | $42,522.00 | 6.06% | 4.42M | 0 | 0% | 2025-09-30 |
| Balyasny Asset Management L.P. | $37,612.00 | 5.36% | 3.91M | -95,349 | -2.38% | 2025-09-30 |
| Affinity Asset Advisors, Llc | $37,196.00 | 5.3% | 3.87M | +281,172 | +7.83% | 2025-09-30 |
| Citadel Advisors Llc | $35,740.00 | 5.1% | 3.72M | +111,076 | +3.08% | 2025-09-30 |
| Vestal Point Capital, Lp | $31,233.00 | 4.45% | 3.25M | +21,839 | +0.68% | 2025-09-30 |
| Woodline Partners Lp | $24,718.00 | 3.52% | 2.57M | 0 | 0% | 2025-09-30 |
| Millennium Management Llc | $22,234.00 | 3.17% | 2.31M | -522,650 | -18.43% | 2025-09-30 |
| Vanguard Group Inc | $21,395.00 | 3.05% | 2.23M | +223,424 | +11.15% | 2025-09-30 |
| Blackrock, Inc. | $20,864.00 | 2.97% | 2.17M | +343,128 | +18.77% | 2025-09-30 |